Pure Global

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old - Trial 2014-004757-14

Access comprehensive clinical trial information for 2014-004757-14 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Vaccines and Diagnostics S.r.l. and is currently status unknown. The study focuses on Influenza.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
2014-004757-14
Trial Details
EU Clinical Trials Register • 2014-004757-14
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

Study Focus

Influenza

Sponsor & Location

Novartis Vaccines and Diagnostics S.r.l.

Novartis Vaccines

Timeline & Enrollment

N/A

N/A

N/A

Primary Outcome

1. Percentage of subjects achieving seroconversion1 or significant increase2 in antibody titer at Day 22 for age group 3;

ICD-10 Classifications

Influenza and pneumonia
Influenza due to identified seasonal influenza virus
Influenza with other manifestations, seasonal influenza virus identified
Influenza with pneumonia, seasonal influenza virus identified
Influenza due to identified zoonotic or pandemic influenza virus

Data Source

EU Clinical Trials Register

2014-004757-14

Non-Device Trial